3 results
Not approvedWill not start
To determine the efficacy and the safety of PREOB, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
Approved WMOCompleted
To determine the efficacy and safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of early stage non-traumatic osteonecrosis of the femoral head.
Approved WMORecruiting
1. The primary objectives of this phase I/II clinical trial is to demonstrate feasibility and evaluate the safety and toxicity of ACT plus vaccination according to CTCAE 4.0 criteria.2. Secondary objectives include the evaluation of the clinical…